Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004234 | 1.00 | MCHR1 (0.51) | MCHR1KCNH2 | |
| SCHEMBL1002752 | 0.90 | MCHR1 (0.54) | MCHR1KCNH2 | |
| SCHEMBL1002750 | 0.90 | MCHR1 (0.54) | MCHR1KCNH2 | |
| SCHEMBL1002472 | 0.88 | MCHR1 (0.52) | MCHR1KCNH2 | |
| SCHEMBL1004678 | 0.88 | MCHR1 (0.54) | MCHR1KCNH2 | |
| SCHEMBL1002473 | 0.88 | MCHR1 (0.52) | MCHR1KCNH2 | |
| SCHEMBL1004679 | 0.88 | MCHR1 (0.54) | MCHR1KCNH2 | |
| SCHEMBL1003635 | 0.87 | MCHR1 (0.52) | MCHR1KCNH2 | |
| SCHEMBL1003634 | 0.87 | MCHR1 (0.52) | MCHR1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL1003655 | 0.84 | MCHR1 (0.49) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | BANYU PHARMACEUTICAL CO., INC. | 2011-01-20 | — | — | US | disclosed |
| EP-2272841-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MC1R, MCHR2, MCHR1 | MCHR1 3/4885KCNH2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.